The "Fast Money" traders give their final trades of the day.» Read More
NEW YORK, June 30- New Jersey Governor Chris Christie's second-in-command gave her pitch to a small crowd at a Philadelphia biotechnology convention in June with her signature move: giving out her cell phone number. "Now, no one from New Jersey! I want the guys that aren't already here in New Jersey. "
June 25- Bristol-Myers Squibb said on Thursday that it would stop efforts to find new antiviral drugs and cut 100 related jobs. The company said a research facility is expected to open in Cambridge, Massachusetts in 2018 and that the expansion of an R&D site in San Francisco Bay Area is likely to be completed by 2016.. Bristol-Myers' stock was up marginally at...
HARTFORD, Conn.— Bristol-Myers Squibb Co. will expand its presence in research centers in Cambridge, Massachusetts, and San Francisco, as it cuts jobs in Connecticut, the biopharmaceutical company announced Thursday. The New York- based company will open a research site in Cambridge— home to the Massachusetts Institute of Technology and Harvard— in 2018 and...
June 22- The U.S. Food and Drug Administration on Monday approved Medicines Co's blood clot preventer Cangrelor, which has faced multiple setbacks since it first entered late-stage studies close to a decade back. Medicines Co has funneled about $200 million into developing Cangrelor over the past decade, which included two unsuccessful trials and a pivotal...
CHICAGO, June 2- Drugmakers including Bristol-Myers Squibb Co and Merck& Co are testing which patients will most benefit from new cancer treatments based on a protein found in their tumors, but that guide, known as a biomarker, may be too unreliable, researchers and health experts said. Competitors Roche Holding, AstraZeneca and Pfizer also have similar drugs in...
RBC Capital Markets' Michael Yee said the selloff of Puma Biotech is in an overreaction and that the stock will represents an opportunity in the long run.
U.S. stocks closed higher on June's first trading day as investors found some encouragement from mixed second-quarter economic reports.
The "Halftime Report" traders give their trades for the second half.
U.S. stock index futures tracked Asian and European equities higher on Monday, after indifferent data from China raised expectations of further stimulus.
The stock-moving news flow started early out of the American Society of Clinical Oncology meeting in Chicago.
Bristol-Myers Squibb's battering after a disappointing drug trial serves as a buying opportunity, "Fast Money" traders said.
*Humana hits record on takeover interest. *Altera rises on report of Intel interest. May 29- U.S. stocks closed lower on Friday as data showed the economy contracted in the first quarter but indexes still posted gains for the month.
Chicago May 29- Bristol-Myers Squibb Co's drug, Opdivo, improved survival in a trial of patients with the most common form of lung cancer, but it did not work in patients who tested negative for a specific protein in their tumors, leading to a nearly 7 percent sell-off in the company's shares on Friday. The Bristol drug was approved by U.S. regulators in December to...
Incyte stands to benefit from unveiling data on its cancer treatments at a conference in the coming days, a biotech analyst said.
It's that time again. With researchers set to convene at the American Society of Clinical Oncology meeting, here are the stocks to watch.
A study sheds light on why the new medicines seem to work for some cancers and not others, NYT reports.
Chicago May 29- Bristol-Myers Squibb Co's drug, Opdivo, improved survival for patients with the most common form of lung cancer, nearly doubling survival for those with high levels of a specific protein in their tumors compared with chemotherapy, according to clinical trial results presented on Friday. The Bristol drug was approved by U.S. regulators in...
BRISTOL-MYERS SQUIBB'S OPDIVO EXTENDS SURVIVAL IN ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER-STUDY.
New data provided to CNBC from eVestment shows the most popular stocks held by institutional funds.
The "Fast Money" traders give their final trades of the day.